Wall Street analysts forecast BIO.B stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast BIO.B stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIO.B is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 312.750
Low
Averages
High
Current: 312.750
Low
Averages
High
Wells Fargo
Brandon Couillard
Hold
Maintains
$320 → $270
2025-04-17
Reason
Wells Fargo
Brandon Couillard
Price Target
$320 → $270
AI Analysis
2025-04-17
Maintains
Hold
Reason
Wells Fargo
Brandon Couillard
Hold
Maintains
$360 → $345
2025-02-12
Reason
Wells Fargo
Brandon Couillard
Price Target
$360 → $345
2025-02-12
Maintains
Hold
Reason
About BIO.B
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis
Nov 25 2025TipRanks
Market Volatility and Technical Analysis: Amid market fluctuations, investors can leverage technical analysis to identify promising stock opportunities, with TipRanks highlighting Wintrust Financial, Bio-Rad Laboratories, and Agree Realty as Strong Buy candidates.
Wintrust Financial Overview: Wintrust Financial is experiencing an upward trend, supported by a Strong Buy rating and 12 bullish signals indicating strong momentum according to TipRanks’ technical analysis.
Bio-Rad Laboratories Insights: Bio-Rad Laboratories also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 1.69, suggesting upward momentum and a Buy signal for the stock.
Agree Realty Corporation Analysis: Agree Realty is rated a Strong Buy based on moving average consensus, with a positive ROC of 2.75, indicating strong upward momentum and a favorable Buy signal.
Continue Reading
Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
Oct 30 2025Yahoo Finance
Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
Access Requirement: Users need to sign in to access their portfolio information.
Continue Reading
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?
How does the company's performance compare to its main competitors in the same sector?